BMB 202
Alternative Names: BMB-202Latest Information Update: 24 Apr 2023
At a glance
- Originator Bright Minds Biosciences
- Class Antidepressants; Anxiolytics
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders; Post-traumatic stress disorders